MD Spine Solutions LLC

MD Spine Solutions LLC was paid $26.27M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Nevada

Rank by total paid#2 of 31

Median peer was paid$269K

This provider vs. median98×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	133,612	$6.76M
2019	191,707	$7.82M
2020	253,491	$7.56M
2021	66,587	$2.32M
2022	12,577	$549K
2023	15,824	$1.14M
2024incomplete	3,422	$118K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	39%	149,760	96,290	$10.16M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	16%	46,791	35,699	$4.29M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	15%	160,011	107,691	$4.07M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	9.7%	50,425	16,341	$2.55M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	9.1%	39,422	26,763	$2.40M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	4.0%	17,185	12,444	$1.06M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	6,575	5,784	$226K
87481		<1%	16,078	13,840	$221K
87653		<1%	16,206	13,936	$189K
87500		<1%	9,870	8,405	$118K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	5,778	4,979	$83K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	5,780	4,985	$75K

63 more codes

87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	5,766	$72K
87086	Culture, bacterial; quantitative colony count, urine	<1%	14,498	$66K
87511		<1%	5,708	$62K
81162		<1%	54	$59K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	513	$51K
81408		<1%	54	$33K
87563		<1%	2,994	$33K
80346		<1%	4,383	$24K
80359		<1%	7,784	$22K
80323		<1%	4,185	$20K
81292		<1%	54	$19K
80361		<1%	4,395	$19K
81317		<1%	54	$19K
81298		<1%	54	$18K
81321		<1%	54	$16K
80356		<1%	4,400	$16K
80354		<1%	4,403	$16K
80363		<1%	4,195	$15K
80325		<1%	4,093	$14K
80348		<1%	4,862	$14K
80353		<1%	3,980	$14K
87529		<1%	790	$14K
80358		<1%	5,411	$13K
80357		<1%	4,153	$13K
80355		<1%	4,222	$11K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,420	$11K
80360		<1%	4,229	$11K
81295		<1%	54	$11K
83992		<1%	3,946	$10K
87186		<1%	3,302	$9K
80339		<1%	4,228	$9K
80335		<1%	4,177	$9K
81406		<1%	100	$8K
80369		<1%	4,343	$8K
80373		<1%	4,417	$8K
80368		<1%	4,329	$7K
80367		<1%	3,790	$7K
80366		<1%	4,223	$7K
80372		<1%	3,915	$7K
80371		<1%	3,804	$7K
80365		<1%	4,832	$7K
81405		<1%	54	$5K
87625		<1%	283	$4K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	164	$4K
81403		<1%	54	$3K
81001		<1%	1,577	$3K
87640		<1%	336	$3K
87486		<1%	350	$3K
87581		<1%	350	$3K
81003		<1%	2,208	$2K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	33	$646.00
87077		<1%	162	$445.33
80362		<1%	54	$246.15
80375		<1%	382	$231.85
80349		<1%	201	$220.14
87150		<1%	55	$202.56
80324		<1%	121	$162.05
80338		<1%	350	$116.92
87541		<1%	56	$63.17
80321		<1%	38	$16.22
80333		0%	120	$0.00
80345		0%	20	$0.00
81479	Unlisted molecular pathology procedure	0%	203	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHOMM, ANGELIQUE (OPERATIONS MANAGER)

Parent organizationMD SPINE SOLUTIONS LLC